Cefazolin sodium target engagement in bacterial lysate
Biochemical assay · Staphylococcus aureus Newman cell lysate; solvent-induced protein precipitation with quantitative mass spectrometry [1]
At 10 µM, cefazolin sodium increased soluble PBP3 abundance versus vehicle (n = 3 per condition), consistent with PBP engagement. Table S3 lists PBP3 among the cefazolin-responsive proteins. This is a lysate stability readout, not a catalytic inhibition, live-cell killing or IC50 assay.
| Endpoint | Reported result | Reference |
|---|---|---|
| PBP3 soluble abundance relative to vehicle | iSPP stabilization Increased; PBP3 listed as stabilized in Table S3 and shown in Figure S10A | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 µM
- Exposure duration
- 30 min compound incubation before solvent challenge
- Method
- Cell-lysate iSPP assay
- Vehicle
- DMSO or ddH2O with corresponding vehicle controls; cefazolin-specific assignment is not explicit in the read main-text methods
- Reported limits
- No cefazolin dose-response IC50; assay measures protein solubility rather than enzyme inhibition. Exact compound-specific vehicle assignment is unclear.
Methods and source locations
Compound reported in the paper: Cefazolin sodium; Compound label in the paper: Cefazolin
Cefazolin sodium target engagement in lysate only.
Table 1; Results: S. aureus target-engagement paragraphs; iSPP Assay and iSPP Data Analysis; SI Figure S10A (PDF p. 16); Table S3 rows 217–229, especially row 222
PBP3 soluble abundance relative to vehicle: Quantitative DIA mass spectrometry after solvent-induced precipitation; n = 3 drug and n = 3 vehicle. Table S3 uses |log2FC| > 0.3 and p < 0.05 for S. aureus. — SI Figure S10A (PDF p. 16); Table S3 rows 217–222; main model-drug assay results and iSPP Data Analysis